header logo image

The Case for and Against Puma Biotechnology, Inc. (PBYI) – StockNewsJournal

June 6th, 2017 11:44 pm

Analyst Ratings
The Case for and Against Puma Biotechnology, Inc. (PBYI)
StockNewsJournal
Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $83.65, up from yesterday's close by 2.07%. Given the stock's recent action, it ...
What Should Investors Make Of The Trading Chart Of Puma Biotechnology, Inc. (PBYI)?NY Stock News
Puma Biotechnology Gets a Buy Rating from Cowen & Co.Analyst Ratings
Puma Biotechnology Inc (PBYI) Upgraded to "Buy" by Zacks Investment ResearchThe Cerbat Gem
Sports Perspectives -Post Registrar -StockNewsMagazine -Zacks
all 32 news articles »

Here is the original post:
The Case for and Against Puma Biotechnology, Inc. (PBYI) - StockNewsJournal

Related Post

Comments are closed.


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick